美沙酮,临床注释,变异和临床注释数据

id	等位基因	注释文本
551	*6	Patients carrying the CYP2D6*6 allele in combination with another no function allele may have decreased methadone dose requirements as compared to patients carrying a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.
397	*4	Patients carrying the CYP2D6*4 allele in combination with another no function allele may have decreased methadone dose requirements as compared to patients carrying a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.
396	*3	Patients carrying the CYP2D6*3 allele in combination with another no function allele may have decreased methadone dose requirements as compared to patients carrying a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.
395	*2xN	Patients carrying the CYP2D6*2xN allele in combination with a normal function allele may have increased methadone dose requirements as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.
394	*1xN	Patients carrying the CYP2D6*1xN allele in combination with a normal function allele may have increased methadone dose requirements as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.
393	*1	Patients carrying the CYP2D6*1 allele in combination with an increased function allele may have increased methadone dose requirements as compared to patients carrying two normal function alleles or two no function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.

等位基因

注释文本

Patients carrying the CYP2D6*6 allele in combination with another no function allele may have decreased methadone dose requirements as compared to patients carrying a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.

397

Patients carrying the CYP2D6*4 allele in combination with another no function allele may have decreased methadone dose requirements as compared to patients carrying a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.

396

Patients carrying the CYP2D6*3 allele in combination with another no function allele may have decreased methadone dose requirements as compared to patients carrying a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.

395

*2xN

Patients carrying the CYP2D6*2xN allele in combination with a normal function allele may have increased methadone dose requirements as compared to patients carrying two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.

394

*1xN

Patients carrying the CYP2D6*1xN allele in combination with a normal function allele may have increased methadone dose requirements as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.

393

Patients carrying the CYP2D6*1 allele in combination with an increased function allele may have increased methadone dose requirements as compared to patients carrying two normal function alleles or two no function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect methadone dose requirements.

id	证据的ID	总结
14438	1451161472	CYP2D6 1/2xN + 2/2xN (assigned as ultrarapid metabolizer phenotype) are associated with increased dose of methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizer genotype.
14437	1451153800	CYP2D6 1/1xN is associated with increased dose of methadone in people with Heroin Dependence as compared to CYP2D6 3/4 + 4/4 + 4/6 (assigned as poor metabolizer genotype phenotype) .
14436	1450374173	CYP2D6 poor and ultrarapid metabolizers are not associated with dose of methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizers.

证据的ID

总结

14438

1451161472

CYP2D6 *1/*2xN + *2/*2xN (assigned as ultrarapid metabolizer phenotype) are associated with increased dose of methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizer genotype.

14437

1451153800

CYP2D6 *1/*1xN is associated with increased dose of methadone in people with Heroin Dependence as compared to CYP2D6 *3/*4 + *4/*4 + *4/*6 (assigned as poor metabolizer genotype phenotype) .

14436

1450374173

CYP2D6 poor and ultrarapid metabolizers are not associated with dose of methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizers.

id	类型	评论
13	Update	CA score added as part of scoring system release. LOE may have automatically changed based on new score but may be subject to further changes upon curator review.
12	Update	Edited phenotype descriptions to include CPIC 'no recommendation'.
11	Update	Added PMID 21589866 to evidence and updated phenotype descriptions
10	Create	Created

类型

Update

CA score added as part of scoring system release. LOE may have automatically changed based on new score but may be subject to further changes upon curator review.

Update

Edited phenotype descriptions to include CPIC 'no recommendation'.

Update

Added PMID 21589866 to evidence and updated phenotype descriptions

Create

Created